Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10967031 | 0.86 | CYP3A4 (0.49) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL27122 | 0.85 | CYP3A4 (0.63) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL17912718 | 0.85 | CYP3A4 (0.63) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL29368386 | 0.85 | CYP3A4 (0.63) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL9246394 | 0.84 | CYP3A4 (0.67) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL10649255 | 0.83 | CYP3A4 (0.56) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| Methyl Alcohol SCHEMBL9746439 | 0.81 | CYP3A4 (0.58) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL28264129 | 0.81 | CYP3A4 (0.58) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL9386715 | 0.81 | CYP3A4 (0.67) | CYP3A4TSHRCYP1A2GABRA1GABRB2 | |
| SCHEMBL17272582 | 0.81 | CYP3A4 (0.57) | CYP3A4TSHRCYP1A2GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637667-B2 | Reactive polyurethane compositions with a low residual monomer content | HENKEL AG & CO. KGAA (DE) | 2017-05-02 | — | — | US | claimed |
| EP-1237971-B1 | ADHESION PROMOTERS FOR MONOMER-FREE REACTIVE POLYURETHANES | HENKEL AG & CO KGAA (DE) | 2010-08-04 | — | — | EP | claimed |
| EP-1434811-B1 | REACTIVE POLYURETHANE COMPOSITIONS WITH LOW RESIDUAL MONOMER CONTENT | HENKEL AG & CO KGAA (DE) | 2010-03-24 | — | — | EP | claimed |
| US-7129312-B1 | Adhesion promoters for monomer-free reactive polyurethanes | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-10-31 | — | — | US | claimed |
| US-20050032973-A1 | Reactive polyurethane compositions with a low residual monomer content | HENKEL AG & CO. KGAA (DE) | 2005-02-10 | — | — | US | claimed |
| US-5686539-A | Thermoplastic compositions | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-11-11 | — | — | US | claimed |
| JP-5194700-A | — | — | None | — | — | JP | disclosed |
| US-9637667-B2 | Reactive polyurethane compositions with a low residual monomer content | HENKEL AG & CO. KGAA (DE) | 2017-05-02 | — | — | US | disclosed |
| EP-1237971-B1 | ADHESION PROMOTERS FOR MONOMER-FREE REACTIVE POLYURETHANES | HENKEL AG & CO KGAA (DE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1434811-B1 | REACTIVE POLYURETHANE COMPOSITIONS WITH LOW RESIDUAL MONOMER CONTENT | HENKEL AG & CO KGAA (DE) | 2010-03-24 | — | — | EP | disclosed |
| US-7129312-B1 | Adhesion promoters for monomer-free reactive polyurethanes | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-10-31 | — | — | US | disclosed |
| US-6908931-B2 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050032973-A1 | Reactive polyurethane compositions with a low residual monomer content | HENKEL AG & CO. KGAA (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| EP-1434811-A1 | REACTIVE POLYURETHANE COMPOSITIONS WITH LOW RESIDUAL MONOMER CONTENT | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003033562-A1 | REACTIVE POLYURETHANE COMPOSITIONS WITH LOW RESIDUAL MONOMER CONTENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-5686539-A | Thermoplastic compositions | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-11-11 | — | — | US | disclosed |
| JP-H05194700-A | RESIN COMPOSITION | SUMITOMO CHEM CO LTD | 1993-08-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | MTNR1A, MTNR1B, PER2 | CYP3A4 342/4885TSHR 234/4885CYP1A2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.